FURI | Fall 2018

Optimizing recombinant protein production for domain antibodies: proof-of-concept

Recent studies in traumatic brain injury (TBI) have found a temporal window where therapeutics on the nanometer scale can cross the blood-brain barrier and enter the parenchyma. Developing protein-based therapeutics is attractive for a number of reasons, yet, the production pipeline for high yield and consistent bioactive recombinant proteins is a major obstacle. This project directly addresses this issue and evaluates the potential to use Brevibacillus host to produce biologically active domain antibody proteins for future use in nanoparticle therapeutics.